Table 1. . Estimated cost of hematologic AE management using the May 2019 data cut-off date.
| Hematologic AE | Frequency of grade ≥3 AE in patients treated with niraparib, n (%) |
AE unit cost† | Mean calculated cost per patient‡ |
||
|---|---|---|---|---|---|
| FSD (n = 315) | ISD (n = 169) | FSD | ISD | ||
| Thrombocytopenia | 114 (36.2) | 25 (14.8) | $12,992.00 | $4701.87 | $1921.89 |
| Anemia | 112 (35.6) | 38 (22.5) | $7830.00 | $2784.00 | $1760.59 |
| Platelet count decreased | 51 (16.2) | 12 (7.1) | $12,992.00 | $2103.47 | $922.51 |
| Neutropenia | 46 (14.6) | 16 (9.5) | $14,466.00 | $2112.50 | $1369.56 |
| Neutrophil count decreased | 28 (8.9) | 9 (5.3) | $14,466.00 | $1285.87 | $770.38 |
| Total cost | $12,987.71 | $6744.93 | |||
†
Cost in the US adjusted to 2020 US dollars.
‡
Costs calculated using the unrounded frequency of grade ≥3 AEs.
AE: Adverse event; FSD: Fixed starting dose; ISD: Individualized starting dose.